Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.